Prescient Therapeutics
Live Investor Briefing
Monday, 31st March 12pm (AEDT)
Please join Prescient Therapeutics CEO James McDonnell for an investor briefing.
In this session, James will discuss:
- How PTX-100’s Phase 1b results – which exceeded expectations and existing drugs – provide a strong basis as we move into Phase 2 clinical trials.
- How the FDA’s Orphan Drug Designation and its Investigational New Drug approval, along with future possible designations, could lead to a registrational study approach fast-tracking PTX-100 into commercialisation – with a A$1bn+ market in the US alone.
- Why PTX-100 in T Cell Lymphomas is just one indication of a much broader RAS family inhibitor approach, which has potential applications for 22% of cancer cases world-wide.
This is a live and interactive online session, and participants are encouraged to ask questions. Don’t miss out, spots are limited.
Can’t make this time, register to receive the replay.
Attend The Session
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
FEATURED SPEAKER
James McDonnell
CEO
James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.
Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing significantly to the company’s acquisition by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.
James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.
Any advice contained within this presentation is general advice and does not consider your personal circumstances, you should consider whether it is appropriate for you. The information we are giving you is for educational purposes only. “Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss.
Past performance is not a reliable indicator of future performance.
This update is being hosted by Reach Markets Pty Ltd (CAR of AFSL 333297) and Reach does not assume responsibility for the accuracy or completeness of any information provided, and any communication from Reach has been prepared with all reasonable care and may be based on unverified information obtained from sources believed to be reliable. However, except to the extent required by law, Reach including its representatives, employees, agents or contractors are not liable to you for any loss or damage resulting directly or indirectly from access to information and do not accept any responsibility for errors and omissions, nor make any warranty or representation as to the reliability, suitability, confidentiality, accuracy, completeness or timeliness of information as it may change without notice and so Reach has no obligation to keep the information current.
Forward Looking Statements relate to intentions, future acts and events that are only predictions and are subject to risks, uncertainties and assumptions, which are outside the control of Reach. These may include commodity prices, currency fluctuations, economic and financial market conditions in various countries and regions, environmental risks and legislative, fiscal or regulatory developments, political risks, project delay or advancement, approvals and cost estimates. Actual values, results or events may be materially different to those expressed or implied and given these uncertainties, readers are cautioned not to place reliance on Forward Looking Statements. Information and views from third parties may be produced solely for convenience and are not endorsed nor reflective of Reach’s position.